Mobia Medical (MOBI) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue rose 73.3% YoY to $15.6M, driven by higher Vivistim adoption and unit sales; nine-month revenue increased 93.0% to $41.2M.

• FY 2026 revenue guidance increased to $57.0M–$57.5M from $54.0M–$56.0M.

• Losses widened with higher commercial, personnel, R&D and public-company costs; $160.7M of cash was expected to fund operations for at least 12 months from issuance.

Financial highlights

• Q3 revenue was $15.6M versus $9.0M; gross profit was $13.0M versus $7.2M, and gross margin was 83.2% versus 79.6%.

• Q3 operating expenses rose 71.1% to $31.5M; operating loss was $18.5M versus $11.3M, and net loss was $17.3M versus $11.4M.

• Nine-month revenue was $41.2M versus $21.3M; net loss was $56.1M versus $32.6M.

• Nine-month operating expenses rose 77.5% to $87.6M, led by SG&A growth.

Outlook and guidance

• FY 2026 revenue guidance is $57.0M–$57.5M, representing stated growth of 78%–79% over FY 2025.

• Planned investment in commercial expansion, patient awareness and access, R&D, regulatory work and clinical studies is expected to increase operating expenses.

• R&D priorities include Vivistim technology advancement, a next-generation system, and exploration of lower-limb impairment and intracerebral hemorrhage indications.